Syngene is a fully integrated partner for biopharma innovation, offering end‑to‑end services across drug discovery, development, clinical research, and manufacturing for both small and large molecules. Our capabilities span traditional and niche modalities, including ADCs, peptides, and oligonucleotides, enabling seamless progression from molecule to market.
Strengthened by expanded biologics capabilities in the U.S. and recognized by TIME as one of the world’s most sustainable companies, Syngene brings together scientific excellence and a deep commitment to the planet. Through innovative, flexible, and efficient development and manufacturing approaches, we help our partners scale rapidly, accelerate go‑to‑market timelines, and expand patient access worldwide.
Connect with our leaders at DCAT Week and discover how our elite‑level, client‑centric approach continues to be a game changer for biopharma partners worldwide.
Who You’ll Meet
Peter Bains
Managing Director and CEO
Rohtash Kumar
Head of CDMO
Small and Large Molecule
Mrinal Kammili
Head of Translational and Clinical Research
Andrew Setikas
Head of Business Development
Small and Large Molecule CDMO
Manoj Babu
VP, Business Development
Small Molecule CDMO
Julien Hugon
VP, Business Development
Small Molecule CDMO
Sudhir Nambiar
Head of DS
Small Molecule CDMO
Purushottam Singnurkar
Head of DP
Small Molecule CDMO
Gopi Krishnan
Head of Large Molecule Development
Dave Kohler
Site Head - Bayview, Maryland, U.S.
Large Molecule CDMO
Pramuch Goel
Head of Corporate Affairs
Sudhir Nambiar
Vice President, Drug Substance Development and Manufacturing
Purushottam Singnurkar
Vice President Pharmaceutical Development
Julien Hugon
Vice President, Business Development
Rajkumar Agarwal
General Manager,
Business Development
Manoj Babu
VP, Development Services
cGMP manufacturing facilities across the U.S. and India
Bayview, Maryland, U.S.
Mammalian Manufacturing
16 KL / 28 KL
Mangalore, India
SM CDMO API manufacturing
~70 KL (expandable)
Biocon Park , Bangalore, India
Mammalian, SM API, DP OSD
LM CDMO: 8 KL
SM CDMO: ~70 KL
Unit 3, Bangalore, India
Mammalian, DP-1/2
LM CDMO: 10 KL / 28KL
DP: Vials, 2 lines, 500 vials/min
The Syngene Advantage
Quality Focus
We are a fully digitized quality organization with a strong compliance track record with global regulators. Our facilities are US FDA, EMA, and PMDA approved, GLP certified, and AAALAC accredited.
Sustainability
As part of our commitment to sustainability, we recycled 63% water, consumed 92% renewable energy, and recycled 95% waste. We had zero environmental violations, and we won the TIME Magazine award for being the most sustainable pharma company in India, and in the Top 20 globally.
Green Chemistry Innovation
Implemented green chemistry across process design, process development, execution, and disposal phases. Also, reduced raw materials, solvents, waste, and disposal.
Robust Supply Chain
A network of 2500+ suppliers across 30+ countries, contracts with global partners, 24X7 local arrangements, and extended support to local partners. Plus, expanded biologics capabilities with our new facility in Bayview, Maryland, U.S.
Syngene’s Enduring Partnership with Bristol Myers Squibb: Advancing More Modalities Together
Syngene has been privileged to partner with Bristol Myers Squibb (BMS) since 1998, supporting its drug discovery and development efforts across multiple modalities and is proud to be extending its work outside of small molecules. Modalities such as antibodies, oligonucleotides and bioconjugates represent a growing area of engagement, and we remain committed to delivering the same level of scientific rigor and operational excellence to BMS helping reduce time and cost to first-in-human studies.
Our experience with BMS is a testament to what can be achieved through deep scientific collaboration and shared purpose.
We look forward to meeting you in New York.
Let’s shape the future of science together.
Syngene International Limited. All rights reserved © 2025